Logo

AbbVie Collaborated with Anima Biotech to Discover and Develop mRNA Biology Modulators

Share this
AbbVie

AbbVie Collaborated with Anima Biotech to Discover and Develop mRNA Biology Modulators

Shots:

  • Anima will receive $42M up front, ~$540M in option fees and R&D milestones across 3 targets & is also eligible for commercial milestones along with royalties on net sales
  • AbbVie gets an option to expand the collaboration with ~3 additional targets & also holds an exclusive right to license and further develop and commercialize the programs
  • The companies collaborated to discover novel mRNA biology modulators against the collaboration targets using Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in oncology and immunology. The collaboration also helps to strengthen AbbVie's capabilities in discovering and developing drugs

Ref: AbbVie | Image: AbbVie

Related News:- AbbVie’s Vraylar (cariprazine) Receives the US FDA’s Approval as an Adjunctive Treatment for Major Depressive Disorder

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions